Pub. Date : 2020 Jan
PMID : 31897145
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |
| 2 | CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |
| 3 | CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |
| 4 | CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |
| 5 | CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |
| 6 | Therefore, erastin/sorafenib regulation of Nrf2 or xCT expression may alter the sensitivity of tumour cells to CDDP. | Cisplatin | NFE2 like bZIP transcription factor 2 | Homo sapiens |